Antigen-specific gene therapy after immunisation reduces the severity of collagen-induced arthritis

Clinical and Developmental Immunology

Volumn 2013, Issue , 2013, Pages

  Eneljung, Tove ^a   Tengvall, Sara ^a   Jirholt, Pernilla ^a   Henningsson, Louise ^a   Holmdahl, Rikard ^b   Gustafsson, Kenth ^c   Gjertsson, Inger ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; AUTOANTIBODY; COLLAGEN TYPE 2; EPITOPE; IMMUNOGLOBULIN G;

ANIMAL; ANTIBODY SPECIFICITY; ARTICLE; BLOOD; EXPERIMENTAL ARTHRITIS; GENE ORDER; GENE THERAPY; GENE VECTOR; GENETICS; IMMUNIZATION; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; LENTIVIRINAE; MALE; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TIME;

ANIMALS; ANTIBODIES; ANTIBODY SPECIFICITY; ARTHRITIS, EXPERIMENTAL; AUTOANTIBODIES; COLLAGEN TYPE II; EPITOPES; GENE ORDER; GENETIC THERAPY; GENETIC VECTORS; IMMUNE TOLERANCE; IMMUNIZATION; IMMUNOGLOBULIN G; LENTIVIRUS; MALE; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY; TIME FACTORS;

EID: 84893786095     PISSN: 17402522     EISSN: 17402530     Source Type: Journal    
DOI: 10.1155/2013/345092     Document Type: Article

References (56)

1. Kukar M., Petryna O., Efthimiou P., Biological targets in the treatment of rheumatoid arthritis: a comprehensive review of current and in-development biological disease modifying anti-rheumatic drugs. Biologics: Targets & Therapy 2009 3 443 457
2. Isaacs J. D., Therapeutic agents for patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor- α antagonists. Expert Opinion on Biological Therapy 2009 9 12 1463 1475 2-s2.0-70450183904 10.1517/14712590903379494
3. Scheinecker C., Redlich K., Smolen J. S., Cytokines as therapeutic targets: advances and limitations. (Pubitemid 351467046)
4. Rosloniec E. F., Whittington K. B., Zaller D. M., Kang A. H., HLA-DR1 (DRB10101) and DR4 (DRB10401) use the same anchor residues for binding an immunodominant peptide derived from human type II collagen. Journal of Immunology 2002 168 1 253 259 2-s2.0-0036134844 (Pubitemid 34014125)
5. Andersson E. C., Hansen B. E., Jacobsen H., Madsen L. S., Andersen C. B., Engberg J., Rothbard J. B., Mcdevitt G. S., Malmström V., Holmdahl R., Svejgaard A., Fugger L., Definition of MHC and T cell receptor contacts in the HLA-DR4-restricted immunodominant epitope in type II collagen and characterization of collagen-induced arthritis in HLA-DR4 and human CD4 transgenic mice. Proceedings of the National Academy of Sciences of the United States of America 1998 95 13 7574 7579 2-s2.0-0032560526
6. Dessen A., Lawrence C. M., Cupo S., Zaller D. M., Wiley D. C., X-ray crystal structure of HLA-DR4 (DRA0101, DRB10401) complexed with a peptide from human collagen II. Immunity 1997 7 4 473 481 2-s2.0-0030701632 (Pubitemid 27508699)
7. Diab B.-Y., Lambert N. C., L'Faqihi F.-E., Loubet-Lescoulié P., de Préval C., Coppin H., Human collagen II peptide 256-271 preferentially binds to HLA-DR molecules associated with susceptibility to rheumatoid arthritis. Immunogenetics 1999 49 1 36 44 2-s2.0-0032959873 10.1007/ s002510050461 (Pubitemid 29039264)
8. Kjellen P., Brunsberg U., Broddefalk J., The structural basis of MHC control of collagen-induced arthritis, binding of the immunodominant type II collagen 256-270 glycopeptide to H-2Aq and H-2Ap molecules. European Journal of Immunology 1998 28 2 755 767 (Pubitemid 28101752)
9. Michaelsson E., Andersson M., Engstrom A., Holmdahl R., Identification of an immunodominant type-II collagen peptide recognized by T cells in H-2(q) mice: self tolerance at the level of determinant selection. European Journal of Immunology 1992 22 7 1819 1825 2-s2.0-0026642137 10.1002/eji.1830220722
10. Rosloniec E. F., Whittington K. B., Brand D. D., Myers L. K., Stuart J. M., Identification of MHC class II and TCR binding residues in the type II collagen immunodominant determinant mediating collagen-induced arthritis. Cellular Immunology 1996 172 1 21 28 2-s2.0-0030601344 10.1006/cimm.1996.0210 (Pubitemid 26295658)
11. Mullazehi M., Wick M. C., Klareskog L., van Vollenhoven R., Ronnelid J., Anti-type II collagen antibodies are associated with early radiographic destruction in rheumatoid arthritis. Arthritis Research & Therapy 2012 14 3, article R100 2-s2.0-84860272864 10.1186/ar3825
12. Myers L. K., Sakurai Y., Tang B., He X., Rosloniec E. F., Stuart J. M., Kang A. H., Peptide-induced suppression of collagen-induced arthritis in HLA-DR1 transgenic mice. Arthritis and Rheumatism 2002 46 12 3369 3377 2-s2.0-0036900514 10.1002/art.10687 (Pubitemid 35453549)
13. Staines N. A., Harper N., Ward F. J., Malmström V., Holmdahl R., Bansal S., Mucosal tolerance and suppression of collagen-induced arthritis (CIA) induced by nasal inhalation of synthetic peptide 184-198 of bovine type II collagen (CII) expressing a dominant T cell epitope. Clinical and Experimental Immunology 1996 103 3 368 375 2-s2.0-0029962104 (Pubitemid 26089942)
14. Miller S. D., Turley D. M., Podojil J. R., Antigen-specific tolerance strategies for the prevention and treatment of autoimmune disease. Nature Reviews Immunology 2007 7 9 665 677 2-s2.0-34548204279 10.1038/nri2153 (Pubitemid 47327394)
15. Larché M., Wraith D. C., Peptide-based therapeutic vaccines for allergic and autoimmune diseases. Nature Medicine 2005 11 4 S69 S76 2-s2.0-17644401678 10.1038/nm1226 (Pubitemid 40562306)
16. Genain C. P., Abel K., Belmar N., Villinger F., Rosenberg D. P., Linington C., Raine C. S., Hauser S. L., Late complications of immune deviation therapy in a nonhuman primate. Science 1996 274 5295 2054 2057 2-s2.0-0030452309 10.1126/science.274.5295.2054 (Pubitemid 27020694)
17. Smith C. E., Eagar T. N., Strominger J. L., Miller S. D., Differential induction of IgE-mediated anaphylaxis after soluble vs. cell-bound tolerogenic peptide therapy of autoimmune encephalomyelitis. Proceedings of the National Academy of Sciences of the United States of America 2005 102 27 9595 9600 2-s2.0-22144479728 10.1073/pnas.0504131102 (Pubitemid 40981726)
18. Honda A., Ametani A., Matsumoto T., Iwaya A., Kano H., Hachimura S., Ohkawa K., Kaminogawa S., Suzuki K., Sercarz E. E., Kumar V., Vaccination with an immunodominant peptide of bovine type II collagen induces an anti-TCR response, and modulates the onset and severity of collage-induced arthritis. International Immunology 2004 16 5 737 745 2-s2.0-2442452758 10.1093/intimm/dxh075 (Pubitemid 38628421)
19. Higuchi K., Kweon M.-N., Fujihashi K., McGhee J. R., Kiyono H., Comparison of nasal and oral tolerance for the prevention of collagen induced murine arthritis. Journal of Rheumatology 2000 27 4 1038 1044 2-s2.0-0034045192 (Pubitemid 30389765)
20. Wei W., Zhang L.-L., Xu J.-H., Xiao F., Bao C.-D., Ni L.-Q., Li X.-F., Wu Y.-Q., Sun L.-Y., Zhang R.-H., Sun B.-L., Xu S.-Q., Liu S., Zhang W., Shen J., Liu H.-X., Wang R.-C., A multicenter, double-blind, randomized, controlled phase III clinical trial of chicken type II collagen in rheumatoid arthritis. Arthritis Research and Therapy 2009 11 6, article R180 2-s2.0-76649114907 10.1186/ar2870
21. Garcia G., Komagata Y., Slavin A. J., Maron R., Weiner H. L., Suppression of collagen-induced arthritis by oral or nasal administration of type II collagen. Journal of Autoimmunity 1999 13 3 315 324 2-s2.0-0032704261 10.1006/jaut.1999.0320
22. Khare S. D., Krco C. J., Griffiths M. M., Luthra H. S., David C. S., Oral administration of an immunodominant human collagen peptide modulates collagen-induced arthritis. Journal of Immunology 1995 155 7 3653 3659 2-s2.0-0029117917
23. Zhu P., Li X.-Y., Wang H.-K., Jia J.-F., Zheng Z.-H., Ding J., Fan C.-M., Oral administration of type-II collagen peptide 250-270 suppresses specific cellular and humoral immune response in collagen-induced arthritis. Clinical Immunology 2007 122 1 75 84 2-s2.0-33845881672 10.1016/j.clim.2006.08.004 (Pubitemid 46026693)
24. Hasselberg A., Schön K., Tarkowski A., Lycke N., Role of CTA1R7K-COL-DD as a novel therapeutic mucosal tolerance-inducing vector for treatment of collagen-induced arthritis. Arthritis and Rheumatism 2009 60 6 1672 1682 2-s2.0-66449089456 10.1002/art.24566
25. +Treg cells and inducing Th1 to Th2 shift in both cells and cytokines. Vaccine 2009 27 5 690 700 2-s2.0-58249113108 10.1016/j.vaccine.2008.11.090
26. Dzhambazov B., Nandakumar K. S., Kihlberg J., Fugger L., Holmdahl R., Vestberg M., Therapeutic vaccination of active arthritis with a glycosylated collagen type II pepticle in complex with MHC class II molecules. Journal of Immunology 2006 176 3 1525 1533 2-s2.0-31144450506 (Pubitemid 43134296)
27. Sakuma T., Barry M. A., Ikeda Y., Lentiviral vectors: basic to translational. The Biochemical Journal 2012 443 3 603 618 2-s2.0-84860133437 10.1042/BJ20120146
28. Charrier S., Stockholm D., Seye K., Opolon P., Taveau M., Gross D.-A., Bucher-Laurent S., Delenda C., Vainchenker W., Danos O., Galy A., A lentiviral vector encoding the human Wiskott-Aldrich syndrome protein corrects immune and cytoskeletal defects in WASP knockout mice. Gene Therapy 2005 12 7 597 606 2-s2.0-20144389599 10.1038/sj.gt.3302440 (Pubitemid 40468107)
29. Chen C.-C., Rivera A., Ron N., Dougherty J. P., Ron Y., A gene therapy approach for treating T-cell-mediated autoimmune diseases. Blood 2001 97 4 886 894 2-s2.0-0035865707 10.1182/blood.V97.4.886 (Pubitemid 32154270)
30. Gjertsson I., Laurie K. L., Devitt J., Howe S. J., Thrasher A. J., Holmdahl R., Gustafsson K., Tolerance induction using lentiviral gene delivery delays onset and severity of collagen II arthritis. Molecular Therapy 2009 17 4 632 640 2-s2.0-63949083969 10.1038/mt.2009.299
31. Srinivasakumar N., HIV-1 vector systems. Somatic Cell and Molecular Genetics 2001 26 1-6 51 81 2-s2.0-0035525956 10.1023/A:1021074613196 (Pubitemid 35332979)
32. Demaison C., Parsley K., Brouns G., Scherr M., Battmer K., Kinnon C., Grez M., Thrasher A. J., High-level transduction and gene expression in hematopoietic repopulating cells using a human imunodeficiency virus type 1-based lentiviral vector containing an internal spleen focus forming virus promoter. Human Gene Therapy 2002 13 7 803 813 2-s2.0-0036252492 10.1089/10430340252898984 (Pubitemid 34493974)
33. Perfetto S. P., Chattopadhyay P. K., Roederer M., Seventeen-colour flow cytometry: unravelling the immune system. Nature Reviews Immunology 2004 4 8 648 655 2-s2.0-3543069879 (Pubitemid 39025050)
34. + T regulatory cells. Journal of Immunology 2010 184 7 3433 3441 2-s2.0-77951638740 10.4049/jimmunol.0904028
35. Batsalova T., Dzhambazov B., Klaczkowska D., Holmdahl R., Mice producing less reactive oxygen species are relatively resistant to collagen glycopeptide vaccination against arthritis. Journal of Immunology 2010 185 5 2701 2709 2-s2.0-78049392108 10.4049/jimmunol.1000385
36. Behrens M., Smart M., Luckey D., Luthra H., Taneja V., To B or not to B: role of B cells in pathogenesis of arthritis in HLA transgenic mice. Journal of Autoimmunity 2011 37 2 95 103 2-s2.0-80052648266 10.1016/j.jaut.2011.05.002
37. Schurgers E., Billiau A., Matthys P., Collagen-induced arthritis as an animal model for rheumatoid arthritis: focus on interferon- γ Journal of Interferon and Cytokine Research 2011 31 12 917 926 2-s2.0-83455200995 10.1089/jir.2011.0056
38. Svensson L., Jirholt J., Holmdahl R., Jansson L., B cell-deficient mice do not develop type II collagen-induced arthritis (CIA). Clinical and Experimental Immunology 1998 111 3 521 526 2-s2.0-0031899715 10.1046/j.1365-2249.1998.00529.x (Pubitemid 28160894)
39. Tang B., Cullins D. L., Zhou J., Zawaski J. A., Park H., Brand D. D., Hasty K. A., Gaber M. W., Stuart J. M., Kang A. H., Myers L. K., Modulation of collagen-induced arthritis by adenovirus-mediated intra-articular expression of modified collagen type II. Arthritis Research and Therapy 2010 12 4, article R136 2-s2.0-78651465342 10.1186/ar3074
40. + cells are interdependent for protection against collagen-induced arthritis. Journal of Immunology 2011 187 9 4654 4666 2-s2.0-80555154833 10.4049/jimmunol.1100530
41. + cell depletion hastens the onset of severe disease in collagen-induced arthritis. Arthritis and Rheumatism 2003 48 5 1452 1460 2-s2.0-0038666539 10.1002/art.11063 (Pubitemid 36554546)
42. Chavele K.-M., Ehrenstein M. R., Regulatory T-cells in systemic lupus erythematosus and rheumatoid arthritis. FEBS Letters 2011 585 23 3603 3610 2-s2.0-81755184312 10.1016/j.febslet.2011.07.043
43. Wright G. P., Stauss H. J., Ehrenstein M. R., Therapeutic potential of Tregs to treat rheumatoid arthritis. Seminars in Immunology 2011 23 3 195 201 2-s2.0-80052894690 10.1016/j.smim.2011.07.004
44. + regulatory T cells with intact suppressive activity but altered cellular localization in murine lupus. American Journal of Pathology 2008 173 6 1682 1692 2-s2.0-57149088827 10.2353/ajpath.2008.080314
45. + regulatory T cells in human autoimmune diseases. Nature Reviews Immunology 2010 10 12 849 859 2-s2.0-78649526238 10.1038/nri2889
46. + regulatory T cells in the human immune system. Nature Reviews Immunology 2010 10 7 490 500 2-s2.0-77954141914 10.1038/nri2785
47. Bettini M., Vignali D. A., Regulatory T cells and inhibitory cytokines in autoimmunity. Current Opinion in Immunology 2009 21 6 612 618 2-s2.0-70449497739 10.1016/j.coi.2009.09.011
48. + regulatory T cells in autoimmune arthritis. Immunological Reviews 2010 233 1 97 111 2-s2.0-73249135168 10.1111/j.0105-2896.2009.00848.x
49. + regulatory T cells. Arthritis and Rheumatism 2005 52 7 2212 2221 2-s2.0-22244448391 10.1002/art.21195 (Pubitemid 40994344)
50. Ehrenstein M. R., Evans J. G., Singh A., Moore S., Warnes G., Isenberg D. A., Mauri C., Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNF α therapy. The Journal of Experimental Medicine 2004 200 3 277 285 2-s2.0-3543140687 10.1084/jem.20040165 (Pubitemid 39031247)
51. Akimova T., Beier U. H., Wang L., Levine M. H., Hancock W. W., Helios expression is a marker of T cell activation and proliferation. PLoS ONE 2011 6 8 2-s2.0-80052287274 10.1371/journal.pone.0024226 e24226
52. Rantapää-Dahlqvist S., de Jong B. A. W., Berglin E., Hallmans G., Wadell G., Stenlund H., Sundin U., Van Venrooij W. J., Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis and Rheumatism 2003 48 10 2741 2749 2-s2.0-18744430797 10.1002/art.11223 (Pubitemid 37280601)
53. Nandakumar K. S., Pathogenic antibody recognition of cartilage. Cell and Tissue Research 2010 339 1 213 220 2-s2.0-72449149203 10.1007/s00441-009-0816-8
54. Rowley M. J., Nandakumar K. S., Holmdahl R., The role of collagen antibodies in mediating arthritis. Modern Rheumatology 2008 18 5 429 441 2-s2.0-53549088056 10.1007/s10165-008-0080-x
55. Nandakumar K. S., Bajtner E., Hill L., Böhm B., Rowley M. J., Burkhardt H., Holmdahl R., Arthritogenic antibodies specific for a major type II collagen triple-helical epitope bind and destabilize cartilage independent of inflammation. Arthritis and Rheumatism 2008 58 1 184 196 2-s2.0-38149006291 10.1002/art.23049
56. Holmdahl R., Andersson M., Goldschmidt T. J., Gustafsson K., Jansson L., Mo J. A., Type II collagen autoimmunity in animals and provocations leading to arthritis. Immunological Reviews 1990 118 1 193 232 2-s2.0-0025572231